175 related articles for article (PubMed ID: 15464317)
1. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
Waksman R; Ajani AE; Pichard AD; Torguson R; Pinnow E; Canos D; Satler LF; Kent KM; Kuchulakanti P; Pappas C; Gambone L; Weissman N; Abbott MC; Lindsay J;
J Am Coll Cardiol; 2004 Oct; 44(7):1386-92. PubMed ID: 15464317
[TBL] [Abstract][Full Text] [Related]
2. Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation.
Stojkovic S; Ostojic M; Nedeljkovic M; Stankovic G; Beleslin B; Vukcevic V; Orlic D; Arandjelovic A; Kostic J; Dikic M; Tomasevic M
Catheter Cardiovasc Interv; 2010 Feb; 75(3):317-25. PubMed ID: 20049961
[TBL] [Abstract][Full Text] [Related]
3. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
Rodriguez AE; Granada JF; Rodriguez-Alemparte M; Vigo CF; Delgado J; Fernandez-Pereira C; Pocovi A; Rodriguez-Granillo AM; Schulz D; Raizner AE; Palacios I; O'Neill W; Kaluza GL; Stone G;
J Am Coll Cardiol; 2006 Apr; 47(8):1522-9. PubMed ID: 16630986
[TBL] [Abstract][Full Text] [Related]
4. Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: a serial intravascular ultrasound study.
Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Feres F; Staico R; Centemero M; Tanajura LF; Abizaid AC; Rodrigues A; Paes A; Mintz GS; Sousa JE
Catheter Cardiovasc Interv; 2005 Dec; 66(4):535-40. PubMed ID: 16283682
[TBL] [Abstract][Full Text] [Related]
5. Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).
Rodríguez AE; Rodríguez Alemparte M; Vigo CF; Fernández Pereira C; Llauradó C; Vetcher D; Pocovi A; Ambrose J
Heart; 2005 Nov; 91(11):1433-7. PubMed ID: 15774608
[TBL] [Abstract][Full Text] [Related]
6. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.
Serruys PW; Ormiston JA; Sianos G; Sousa JE; Grube E; den Heijer P; de Feyter P; Buszman P; Schömig A; Marco J; Polonski L; Thuesen L; Zeiher AM; Bett JH; Suttorp MJ; Glogar HD; Pitney M; Wilkins GT; Whitbourn R; Veldhof S; Miquel K; Johnson R; Coleman L; Virmani R;
J Am Coll Cardiol; 2004 Oct; 44(7):1363-7. PubMed ID: 15464314
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial).
Rodriguez AE; Alemparte MR; Vigo CF; Pereira CF; Llaurado C; Russo M; Virmani R; Ambrose JA
J Invasive Cardiol; 2003 Oct; 15(10):581-4. PubMed ID: 14519892
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
Hausleiter J; Kastrati A; Mehilli J; Vogeser M; Zohlnhöfer D; Schühlen H; Goos C; Pache J; Dotzer F; Pogatsa-Murray G; Dirschinger J; Heemann U; Schömig A;
Circulation; 2004 Aug; 110(7):790-5. PubMed ID: 15302787
[TBL] [Abstract][Full Text] [Related]
9. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
[TBL] [Abstract][Full Text] [Related]
11. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
[TBL] [Abstract][Full Text] [Related]
12. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.
Moussa I; Leon MB; Baim DS; O'Neill WW; Popma JJ; Buchbinder M; Midwall J; Simonton CA; Keim E; Wang P; Kuntz RE; Moses JW
Circulation; 2004 May; 109(19):2273-8. PubMed ID: 15123524
[TBL] [Abstract][Full Text] [Related]
13. The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions.
Moses JW; Weisz G; Mishkel G; Caputo R; O'shaughnessey C; Wong SC; Fischell TA; Mooney M; Williams DO; Popma JJ; Fitzgerald P; Smith S; Kuntz RE; Collins M; Cohen SA; Leon MB
Catheter Cardiovasc Interv; 2007 Oct; 70(4):505-12. PubMed ID: 17896408
[TBL] [Abstract][Full Text] [Related]
14. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
Grube E; Sonoda S; Ikeno F; Honda Y; Kar S; Chan C; Gerckens U; Lansky AJ; Fitzgerald PJ
Circulation; 2004 May; 109(18):2168-71. PubMed ID: 15123533
[TBL] [Abstract][Full Text] [Related]
15. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
16. Is there delayed restenosis in patients with coronary artery disease treated with sirolimus-eluting stent?
Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
Coron Artery Dis; 2007 Jun; 18(4):293-8. PubMed ID: 17496493
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus-eluting cobalt alloyed stents in treating patients with coronary artery disease: six-month angiographic and one-year clinical follow-up result. A prospective, historically controlled, multi-center clinical study.
Zhang Q; Xu B; Yang YJ; Zhang RY; Li JP; Qiao SB; Zhang JS; Hu J; Qin XW; Hong T; Chen JL; Huo Y; Shen WF; Gao RL
Chin Med J (Engl); 2007 Apr; 120(7):533-8. PubMed ID: 17442198
[TBL] [Abstract][Full Text] [Related]
18. Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up.
Cernigliaro C; Sansa M; Vitrella G; Verde A; Bongo AS; Giuliani L; Novelli E
Cardiology; 2010; 115(1):77-86. PubMed ID: 19887796
[TBL] [Abstract][Full Text] [Related]
19. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
